Corbus Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:CRBP)

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) saw some unusual options trading on Monday. Stock traders bought 7,228 call options on the company. This represents an increase of 523% compared to the typical volume of 1,160 call options.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Corbus Pharmaceuticals in a report on Monday. Oppenheimer lowered their price objective on shares of Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a research note on Friday, August 7th. Wall Street Zen lowered shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Finally, Mizuho set a $33.00 target price on Corbus Pharmaceuticals in a research report on Thursday, August 13th. Eight research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Corbus Pharmaceuticals Stock Down 14.4%

Corbus Pharmaceuticals stock opened at $6.92 on Wednesday. The stock has a 50-day moving average price of $9.70 and a 200 day moving average price of $9.44. The company has a market capitalization of $129.20 million, a price-to-earnings ratio of -1.12 and a beta of 2.63. Corbus Pharmaceuticals has a 52 week low of $6.32 and a 52 week high of $20.56.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.55). Research analysts anticipate that Corbus Pharmaceuticals will post -5.62 EPS for the current fiscal year.

Insider Buying and Selling at Corbus Pharmaceuticals

In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 17,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $171,360.00. Following the completion of the sale, the chief executive officer owned 157,316 shares of the company’s stock, valued at approximately $1,585,745.28. This trade represents a 9.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sean Moran sold 12,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $120,960.00. Following the sale, the chief financial officer owned 84,694 shares in the company, valued at $853,715.52. The trade was a 12.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 31,000 shares of company stock worth $308,000. 3.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Engineers Gate Manager LP boosted its holdings in Corbus Pharmaceuticals by 109.9% in the second quarter. Engineers Gate Manager LP now owns 29,800 shares of the biopharmaceutical company’s stock valued at $280,000 after purchasing an additional 15,600 shares during the last quarter. Pale Fire Capital SE raised its stake in shares of Corbus Pharmaceuticals by 13.8% during the 2nd quarter. Pale Fire Capital SE now owns 24,301 shares of the biopharmaceutical company’s stock valued at $228,000 after buying an additional 2,951 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Corbus Pharmaceuticals during the 2nd quarter valued at about $425,000. Seven Fleet Capital Management LP lifted its holdings in shares of Corbus Pharmaceuticals by 51.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 85,687 shares of the biopharmaceutical company’s stock valued at $805,000 after buying an additional 28,937 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Corbus Pharmaceuticals by 53,592.3% in the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 13,934 shares during the period. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals News Summary

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Corbus reported positive topline results from the CANYON-1 Phase 1b trial of oral CRB-913 in obesity. The 60 mg dose produced statistically significant, clinically meaningful average weight loss of 5% after 12 weeks, with no plateau observed. The drug was generally well tolerated, with psychiatric adverse events broadly comparable to GLP-1 medicines and an emerging favorable gastrointestinal tolerability profile. Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study
• Positive Sentiment: The data support CRB-913’s potential as an oral, non-incretin obesity treatment, and the company plans a late-breaking presentation at ObesityWeek 2026. The results prompted HC Wainwright to reaffirm its “buy” rating and maintain a $35 price target, implying substantial upside from recent levels. Corbus Pharmaceuticals Obesity Drug Avoids Depressive Effects
• Neutral Sentiment: Trading in CRBP options was unusually active, with call purchases approximately 523% above typical volume on Monday. This may indicate speculative interest following the trial announcement, but it does not establish the direction of the stock.
• Negative Sentiment: Put-option purchases surged approximately 690% above average on Tuesday, signaling increased bearish hedging or speculation and potentially contributing to short-term selling pressure.
• Negative Sentiment: Director Yong Ben sold 2,000 shares for approximately $15,680, reducing his position by 17.57%. While the transaction is relatively small, insider selling can weigh on investor sentiment.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research programs are designed to target biological pathways involved in tumor growth, immune regulation and tissue fibrosis.

Corbus’s oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, a protein expressed on several solid tumors. The company is also developing CRB-601, an investigational monoclonal antibody directed at the alpha v beta 6 integrin, a target associated with tumor biology and fibrotic disease.